SURROZEN INC (SRZN)
Health Care · Clinical-stage biopharmaceutical / oncology · NASDAQ
Surrozen is a clinical-stage biotechnology company developing regenerative therapies that harness the body's Wnt signaling pathway to repair tissue damage.
What SURROZEN INC does
Surrozen is a biopharmaceutical company focused on discovering and developing therapeutic product candidates targeting the Wnt signaling pathway. The company leverages its proprietary drug discovery and development capabilities to create candidates for oncology and regenerative medicine applications. Surrozen is currently in clinical trials with its pipeline candidates and is working to obtain regulatory approval while managing its operations and seeking funding to support ongoing development activities.
Themes: regenerative medicine, Wnt signaling pathway, drug discovery, biotechnology
Fundamentals
- Price$23.99 as of 2026-08-21 close
- Market cap$282M as of 2026-08-21
- 1-year return+111.4% 2025-08-21 close $11.35 → 2026-08-21 close $23.99
- P/En/a negative earnings
- Net margin-4571.1% as of 2026-08-24
- ROE+58.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-35.6% as of 2026-08-24
- Beta0.53 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How SRZN compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SURROZEN INC looks technically
SURROZEN INC (SRZN) is trading 3.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 6 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 11 trading days ago. It is 31.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.08 | $23.08 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.30 | $23.30 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 6 trading days ago — a "death cross", a bearish long-term signal | 6 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 3.0% above | +3.0% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.7 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($20.73 to $27.32) — its "stochastic" reading is 49 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 49.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $35.00 | $35.00 |
|---|---|---|
| From the 52-week high | it is 31.5% below its 52-week high (its highest price of the past year) | -31.5% |
| Above the 52-week low | it is 137.3% above its 52-week low (its lowest price of the past year) | +137.3% |
| Below the 52-week high | it is 31.5% below its highest point of the past year | 31.5% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 18 trading days ago | 18 sessions |
| All-time high | its highest closing price on record is $208.96 (set on 2021-09-17) | $208.96 |
| Given back of the 52-week move | over the past year its closes ranged ($10.85 to $34.13), and it has given back roughly a third of its rise from last year’s low — 44% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $19.00 to $19.74. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 43.6% |
| From the all-time high | it is 88.5% below its all-time high | -88.5% |
| Nearest price level | it is trading 1.9% above a support level at $23.52 — a price it turned at four times since 2026-02-26, most recently on 2026-07-21. Since 2024-08-21 it has 14 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.9% |
| All-time low | its lowest closing price on record is $4.48 (set on 2023-11-09) | $4.48 |
| Above the all-time low | it is 435.8% above its all-time low | +435.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 80% of the past ~6 months) | 80th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.77 between its high and its low — about 7.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.77 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.06 and $26.52 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.06 – $22.79 – $26.52 |
| Typical daily range (% of price) | its price moves about 7.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.4% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges above its 200-day average price (3.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.60× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 14.8% above the previous close 10 sessions ago and has not traded back through the level it left behind at 21.64 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +14.8% |
| Gap filled | a 2.2% gap up opened on 2026-08-11 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 8 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.0 percentage points (the stock gained 4.3% while the market gained 2.3%) | +2.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.5 percentage points (the stock lost 11.4% while the market gained 3.1%) | -14.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.8 percentage points (the stock lost 9.8% while the market gained 11.1%) | -20.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 90.9 percentage points (the stock gained 111.4% while the market gained 20.5%) | +90.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 18.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $24.39 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -1.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $24.09 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -0.4% |
Price levels it has turned at before
SRZN last closed at $23.99 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.52 | Support | 1.9% below the last close | turned there four times · 2026-02-26 to 2026-07-21 |
| $25.02 | Resistance | 4.3% above the last close | turned there three times · 2025-12-12 to 2026-05-20 |
| $27.05 | Resistance | 12.8% above the last close | turned there three times · 2026-04-27 to 2026-08-07 |
| $18.14 | Support | 24.4% below the last close | turned there twice · 2025-01-03 to 2026-07-29 |
| $14.39 | Support | 40.0% below the last close | turned there twice · 2025-10-22 to 2025-10-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$44.60 range $40.00 – $51.00; median $44.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SRZN
- Consensus EPS estimate-$1.32 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial capital requirements to fund ongoing research and clinical development.","Uncertainty inherent in the clinical trial and regulatory approval process for novel therapeutics.","Significant liabilities related to tranche and warrant agreements affecting the balance sheet."]
What changed in the latest 10-Q
AI-assisted comparison of SRZN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 annual report filed March 23, 2026; older filing references 2024 annual report filed March 31, 2025
- Newer filing states SZN-8141 'anticipates submitting an IND for SZN-8141 in the second half of 2026'
- Newer filing describes SZN-8143 as combining 'Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6, antagonism' for treatment of 'DME, wet AMD, and uveitic macular edema, or UME'
- Newer filing includes research programs section describing corneal endothelial disease and retinal research models without specific product candidate designation
- Newer filing specifies 'localized delivery enables controlled therapeutic modulation' for ophthalmology approach
- Removed:
- Older filing stated strategic focus on discovering candidates for 'a broad range of organs and tissues' and listed diseases in intestine, liver, lung, kidney, cochlea, skin, pancreas and central nervous system
- Older filing contained language 'we are pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics'
- Older filing stated SZN-8141 nominated 'in the third quarter of 2024' and expected to 'file an Investigational New Drug application and commence clinical studies for SZN-8141 in 2026'
- Older filing stated SZN-8143 nominated 'in the third quarter of 2024'
- Older filing included dedicated section on 'SZN-113 for Fuchs' Endothelial Corneal Dystrophy and Geographic Atrophy' as a development candidate targeting Fzd127
- Reworded:
- Newer: 'product candidates to selectively modulate the Wnt pathway'; Older: 'drug candidates to selectively modulate the Wnt pathway'
- Newer: 'our current strategic focus is ophthalmology'; Older: 'current focus in ophthalmology'
- Newer: mission 'transform the treatment of serious ophthalmic disease'; Older: 'transform the treatment of serious disease'
- Newer: 'restoration of tissue structure and function in serious eye diseases'; Older: referred to 'severe diseases' across multiple organs
- Newer describes SZN-8141 as combining Fzd4 and VEGF with potential over 'single mechanism agents'; Older: 'single agents'
- Newer: 'retinopathy indications'; Older: 'retinal vascular diseases'
- Newer: research programs section describes potential without specific candidate naming; Older: SZN-113 was explicitly named development candidate
- Notes:
- The newer MD&A appears truncated mid-sentence at 'SZN-413 for Retinal Diseases' section, limiting full comparison of that subsection
- Older filing text also appears truncated at end of SZN-413 section
- Strategic shift from multi-indication approach to ophthalmology-focused approach is evident but text does not explicitly state discontinuation of non-ophthalmic programs
Risk Factors
- Added:
- Newer filing (2026-05-06) shows financial data as of March 31, 2026, whereas older filing (2025-11-07) shows data as of September 30, 2025
- Newer filing includes 'Collaboration and license revenue' of $5,000 in Q1 2026, whereas older filing shows $0 for Q3 2025
- Newer filing shows 'Accounts receivable' of $5,000 as of March 31, 2026, versus $2,317 as of September 30, 2025
- Newer filing shows increased 'Accounts receivable - related party' of $0 as of March 31, 2026, versus $251 as of September 30, 2025
- Newer filing shows 'Tranche liability' of $235,517 as of March 31, 2026, versus $51,651 as of September 30, 2025
- Newer filing shows 'Warrant liabilities' of $148,923 as of March 31, 2026, versus $53,544 as of September 30, 2025
- Newer filing shows 'Total stockholders' deficit' of $(278,147) as of March 31, 2026, versus $(23,515) as of September 30, 2025
- Newer filing shows 'Loss on change in fair value of tranche liability' of $(76,855) for Q1 2026, versus $(40,748) for Q3 2025
- Newer filing shows 'Other (expense) income, net' of $(41,106) for Q1 2026, versus $(20,921) for Q3 2025
- Removed:
- Older filing (2025-11-07) included 'Warrant asset' of $845 as of September 30, 2025; newer filing (2026-05-06) does not list this line item as of March 31, 2026
- Older filing included 'Research service revenue – related party' of $983 for Q3 2025; newer filing shows $0 for Q1 2026
- Older filing included 'Loss on issuance of common stock, pre-funded warrants and warrants in the 2024 PIPE' in nine-month results; newer filing does not include this item
- Older filing included 'Gain on settlement of tranche liability' of $0 for Q3 2025 but $1,117 for nine-month period; newer filing shows $0 for Q1 2026
- Reworded:
- Older filing references 'preclinical and clinical trials with respect to SZN-413, SZN-8141, SZN-8143, SZN-113 and potential future drug candidates'; newer filing generalizes to 'current and potential future product candidates' without specific drug names
- Older filing states 'our ability to identify, develop and commercialize drug candidates'; newer filing states 'our ability to identify, develop and commercialize product candidates' (changed 'drug candidates' to 'product candidates')
- Older filing references 'three and nine months ended September 30, 2025'; newer filing references 'three months ended March 31, 2026'
- Older filing table of contents shows 'Item 1A. Risk Factors' on page 29; newer filing shows page 26
- Notes:
- The two filings cover different reporting periods (Q3 2025 nine-month period versus Q1 2026 three-month period), so financial statement comparisons reflect different time periods rather than direct comparable periods
- The provided newer filing text appears truncated and incomplete (ends mid-table in 'Condens'), limiting full assessment of all changes in the Risk Factors section itself
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($7M) — 1 selling insider
- Last 180 days0 buys · 5 sells ($7M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-22. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SRZN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding SRZN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 140,172
- Reported value $4,083,209
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SRZN had 1,150,387 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SRZN had 9.79% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.06 days to cover at the same settlement.
- Reported short interest (shares) 1,150,387
- Short interest (% of shares outstanding) 9.79%
- Prior settlement (shares) 970,957
- Reported change 18.48%
- Days to cover (reported) 4.06
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Genentech (subsidiary of Roche)
- Novartis (NVS)
- Eli Lilly (LLY)
- Regeneron Pharmaceuticals (REGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SRZN vs…
SURROZEN INC is found in…
SRZN ranks in…
Frequently asked questions
What does SURROZEN INC (SRZN) do?
Surrozen is a biopharmaceutical company focused on discovering and developing therapeutic product candidates targeting the Wnt signaling pathway. The company leverages its proprietary drug discovery and development capabilities to create candidates for oncology and regenerative medicine applications.
What sector is SURROZEN INC (SRZN) in?
SURROZEN INC (SRZN) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical / oncology. It trades on NASDAQ.
Who are SURROZEN INC's (SRZN) competitors?
Notable peers of SURROZEN INC (SRZN) include Amgen, Genentech (subsidiary of Roche), Novartis, Eli Lilly and Regeneron Pharmaceuticals. This peer set is informational only — not financial advice.
Is SURROZEN INC (SRZN) overbought or oversold right now?
SURROZEN INC (SRZN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SRZN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.